• Molecular NameEptifibatide
  • Synonymeptifibatide; Integrelin; Intrifiban
  • Weight831.977
  • Drugbank_IDDB00063
  • ACS_NO188627-80-7
  • Show 3D model
  • LogP (experiment)N/A
  • LogP (predicted, AB/LogP v2.0)-1.15
  • pkaN/A
  • LogD (pH=7, predicted)-3.65
  • Solubility (experiment)N/A
  • LogS (predicted, ACD/Labs)(ph=7)0.04
  • LogSw (predicted, AB/LogsW2.0)0.2
  • Sw (mg/ml) (predicted, ACD/Labs)911.77
  • No.of HBond Donors13
  • No.of HBond Acceptors20
  • No.of Rotatable Bonds11
  • TPSA374.49
  • StatusFDA approved
  • AdministrationIV only
  • PharmacologyAn antiplatelet drug that selectively blocks the platelet glycoprotein IIb/IIIa receptor.
  • Absorption_valueN/A
  • Absorption (description)N/A
  • Caco_2N/A
  • Bioavailability0.0
  • Protein binding25.0
  • Volume of distribution (VD)N/A
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmThe majority of the drug excreted in the urine as eptifibatide, deamidated eptifibatide, and other, more polar metabolites.
  • Half life2.5 h
  • ExcretionRenal
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicityBleeding is the most importand advese effect of Eptifibatide. Hypoteinsion is the most serious non-bleeding event. Other adverse effects reported include intracranial hemorragie and stroke, thrombocytopenia, allergic reactions.
  • LD50 (rat)N/A
  • LD50 (mouse)N/A